nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—SLC6A4—conduct disorder	0.514	0.565	CbGaD
Duloxetine—HTR2A—conduct disorder	0.395	0.435	CbGaD
Duloxetine—SLC6A3—Clearance of dopamine—COMT—conduct disorder	0.00722	0.1	CbGpPWpGaD
Duloxetine—SLC6A3—Clearance of dopamine—MAOA—conduct disorder	0.00716	0.0997	CbGpPWpGaD
Duloxetine—SLC6A2—autonomic nervous system—conduct disorder	0.00515	0.379	CbGeAlD
Duloxetine—SLC6A4—Serotonin Transporter Activity—MAOA—conduct disorder	0.00333	0.0463	CbGpPWpGaD
Duloxetine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—conduct disorder	0.00329	0.0458	CbGpPWpGaD
Duloxetine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—conduct disorder	0.00327	0.0455	CbGpPWpGaD
Duloxetine—HTR2A—autonomic nervous system—conduct disorder	0.0031	0.228	CbGeAlD
Duloxetine—HTR6—Serotonin receptors—HTR2A—conduct disorder	0.00238	0.0331	CbGpPWpGaD
Duloxetine—HTR2C—Serotonin receptors—HTR2A—conduct disorder	0.00175	0.0244	CbGpPWpGaD
Duloxetine—Protriptyline—SLC6A4—conduct disorder	0.00171	0.335	CrCbGaD
Duloxetine—HTR6—Monoamine GPCRs—DRD4—conduct disorder	0.00162	0.0226	CbGpPWpGaD
Duloxetine—SLC6A2—Monoamine Transport—SLC6A4—conduct disorder	0.00162	0.0225	CbGpPWpGaD
Duloxetine—NPY1R—brain—conduct disorder	0.00147	0.108	CbGeAlD
Duloxetine—SLC6A3—Monoamine Transport—SLC6A4—conduct disorder	0.00143	0.0199	CbGpPWpGaD
Duloxetine—HTR6—Amine ligand-binding receptors—DRD4—conduct disorder	0.00137	0.019	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0013	0.0181	CbGpPWpGaD
Duloxetine—HTR2C—Monoamine GPCRs—DRD4—conduct disorder	0.0012	0.0167	CbGpPWpGaD
Duloxetine—Fluoxetine—SLC6A4—conduct disorder	0.00117	0.229	CrCbGaD
Duloxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—conduct disorder	0.00116	0.0162	CbGpPWpGaD
Duloxetine—CYP1A2—Methylation—COMT—conduct disorder	0.00109	0.0152	CbGpPWpGaD
Duloxetine—HTR6—Monoamine GPCRs—HTR2A—conduct disorder	0.00106	0.0148	CbGpPWpGaD
Duloxetine—HTR2A—Monoamine GPCRs—DRD4—conduct disorder	0.00104	0.0145	CbGpPWpGaD
Duloxetine—HTR6—brain—conduct disorder	0.00103	0.0759	CbGeAlD
Duloxetine—HTR6—G alpha (s) signalling events—CGA—conduct disorder	0.00101	0.014	CbGpPWpGaD
Duloxetine—HTR2C—Amine ligand-binding receptors—DRD4—conduct disorder	0.00101	0.014	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CGA—conduct disorder	0.00099	0.0138	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—DRD4—conduct disorder	0.000916	0.0127	CbGpPWpGaD
Duloxetine—Fluoxetine—HTR2A—conduct disorder	0.000896	0.176	CrCbGaD
Duloxetine—HTR6—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000891	0.0124	CbGpPWpGaD
Duloxetine—HTR2A—Amine ligand-binding receptors—DRD4—conduct disorder	0.000873	0.0122	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00085	0.0118	CbGpPWpGaD
Duloxetine—HTR2C—Monoamine GPCRs—HTR2A—conduct disorder	0.00078	0.0109	CbGpPWpGaD
Duloxetine—Atomoxetine—SLC6A4—conduct disorder	0.000749	0.147	CrCbGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000728	0.0101	CbGpPWpGaD
Duloxetine—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.000683	0.00951	CbGpPWpGaD
Duloxetine—HTR2C—Amine ligand-binding receptors—HTR2A—conduct disorder	0.000656	0.00913	CbGpPWpGaD
Duloxetine—SLC6A3—brain—conduct disorder	0.000618	0.0454	CbGeAlD
Duloxetine—HTR2C—brain—conduct disorder	0.000597	0.0439	CbGeAlD
Duloxetine—Atomoxetine—HTR2A—conduct disorder	0.000576	0.113	CrCbGaD
Duloxetine—SLC6A4—brain—conduct disorder	0.000566	0.0416	CbGeAlD
Duloxetine—NPY1R—GPCR downstream signaling—CGA—conduct disorder	0.000559	0.00779	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000554	0.00772	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—DRD4—conduct disorder	0.000554	0.00772	CbGpPWpGaD
Duloxetine—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.000547	0.00761	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—GABRA2—conduct disorder	0.000521	0.00725	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CGA—conduct disorder	0.000508	0.00707	CbGpPWpGaD
Duloxetine—SLC6A2—brain—conduct disorder	0.000498	0.0366	CbGeAlD
Duloxetine—SLC6A2—NRF2 pathway—SLC6A4—conduct disorder	0.00048	0.00669	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00048	0.00668	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000475	0.00661	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.000463	0.00644	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—DRD4—conduct disorder	0.000461	0.00642	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—SLC6A4—conduct disorder	0.000425	0.00592	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—DRD4—conduct disorder	0.000407	0.00566	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—GABRA2—conduct disorder	0.000399	0.00556	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.000399	0.00555	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CGA—conduct disorder	0.000365	0.00508	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—HTR2A—conduct disorder	0.000362	0.00504	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000353	0.00492	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.000325	0.00452	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.000319	0.00444	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000313	0.00436	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—DRD4—conduct disorder	0.000313	0.00436	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.000307	0.00427	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CGA—conduct disorder	0.0003	0.00418	CbGpPWpGaD
Duloxetine—HTR2A—brain—conduct disorder	0.0003	0.022	CbGeAlD
Duloxetine—NPY1R—Signaling by GPCR—DRD4—conduct disorder	0.000285	0.00396	CbGpPWpGaD
Duloxetine—CYP2D6—brain—conduct disorder	0.000273	0.0201	CbGeAlD
Duloxetine—HTR2C—GPCR ligand binding—CGA—conduct disorder	0.000269	0.00374	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000269	0.00374	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—COMT—conduct disorder	0.000251	0.00349	CbGpPWpGaD
Duloxetine—SLC6A3—Transmission across Chemical Synapses—MAOA—conduct disorder	0.000249	0.00347	CbGpPWpGaD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000248	0.00345	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000242	0.00337	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—WASF1—conduct disorder	0.000241	0.00335	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00024	0.00334	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CGA—conduct disorder	0.000234	0.00325	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.000231	0.00321	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000215	0.00299	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00021	0.00292	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CGA—conduct disorder	0.000206	0.00287	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000205	0.00285	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—DRD4—conduct disorder	0.000205	0.00285	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HTR2A—conduct disorder	0.000204	0.00285	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0002	0.00279	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000198	0.00275	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—HTR2A—conduct disorder	0.000195	0.00271	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—COMT—conduct disorder	0.000192	0.00267	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.000192	0.00267	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—MAOA—conduct disorder	0.000191	0.00265	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CGA—conduct disorder	0.000187	0.00261	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HTR2A—conduct disorder	0.000186	0.00258	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000175	0.00244	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000174	0.00243	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000172	0.0024	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.000172	0.00239	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—DRD4—conduct disorder	0.000168	0.00234	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CGA—conduct disorder	0.000152	0.00212	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.000151	0.0021	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—DRD4—conduct disorder	0.000151	0.0021	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—EP300—conduct disorder	0.000141	0.00196	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000138	0.00192	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000138	0.00192	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CGA—conduct disorder	0.000138	0.00192	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HTR2A—conduct disorder	0.000133	0.00186	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000132	0.00184	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CGA—conduct disorder	0.000132	0.00184	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000132	0.00183	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—DRD4—conduct disorder	0.000131	0.00182	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000131	0.00182	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.000129	0.0018	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CGA—conduct disorder	0.00012	0.00167	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—DRD4—conduct disorder	0.000116	0.00161	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—COMT—conduct disorder	0.000112	0.00156	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.000111	0.00155	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CGA—conduct disorder	0.000111	0.00154	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.000111	0.00154	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HTR2A—conduct disorder	0.00011	0.00153	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—DRD4—conduct disorder	0.000105	0.00146	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.000104	0.00144	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HTR2A—conduct disorder	9.83e-05	0.00137	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	9.55e-05	0.00133	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—WASF1—conduct disorder	8.87e-05	0.00124	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—DRD4—conduct disorder	8.51e-05	0.00118	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CGA—conduct disorder	8.15e-05	0.00113	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—DRD4—conduct disorder	7.73e-05	0.00108	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR2A—conduct disorder	7.54e-05	0.00105	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—DRD4—conduct disorder	7.39e-05	0.00103	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CGA—conduct disorder	7.08e-05	0.000985	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR2A—conduct disorder	6.85e-05	0.000953	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—DRD4—conduct disorder	6.71e-05	0.000934	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—WASF1—conduct disorder	6.53e-05	0.00091	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DRD4—conduct disorder	6.2e-05	0.000863	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EP300—conduct disorder	5.81e-05	0.000809	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—WASF1—conduct disorder	5.67e-05	0.00079	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—conduct disorder	5.55e-05	0.000773	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—conduct disorder	5.04e-05	0.000702	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CGA—conduct disorder	5.02e-05	0.000699	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DRD4—conduct disorder	4.57e-05	0.000636	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CGA—conduct disorder	4.25e-05	0.000592	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—conduct disorder	4.05e-05	0.000563	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DRD4—conduct disorder	3.96e-05	0.000552	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—conduct disorder	2.98e-05	0.000415	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—COMT—conduct disorder	2.27e-05	0.000315	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MAOA—conduct disorder	2.25e-05	0.000313	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EP300—conduct disorder	2.14e-05	0.000298	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—COMT—conduct disorder	1.92e-05	0.000267	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MAOA—conduct disorder	1.91e-05	0.000265	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	1.85e-05	0.000257	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EP300—conduct disorder	1.58e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EP300—conduct disorder	1.37e-05	0.000191	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EP300—conduct disorder	9.72e-06	0.000135	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EP300—conduct disorder	8.23e-06	0.000115	CbGpPWpGaD
